Under a trading plan, Stoke Therapeutics (STOK) medical chief sells 1,051 shares.
Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 1,051 shares of common stock on October 1, 2026, at a weighted-average price of $26.1594 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted in November 2025. After the sale, Ticho directly held 19,059 shares.
Stoke Therapeutics (NASDAQ:STOK) Insider Sells 1,051 Shares of Stock
Stoke Therapeutics (NASDAQ:STOK) insider Barry Ticho sold 1,051 shares of the company's stock for $27,494.16 on October 1st, reducing his stake by 5.23% to 19,059 shares. The sale was executed under a pre-arranged Rule 10b5-1 plan. Despite the insider selling and recent stock price declines, analysts maintain a "Moderate Buy" rating with a consensus price target of $44.25, and institutional investors have been increasing their positions.
Stoke Therapeutics (NASDAQ:STOK) Stock: Insider Jonathan Allan Sells 627 Shares
Stoke Therapeutics General Counsel Jonathan Allan sold 627 shares of STOK stock at an average price of $26.33, totaling $16,508.91, through a pre-arranged Rule 10b5-1 plan. This transaction reduced his direct holdings to 20,598 shares. The company's stock recently traded at $25.62, near its 12-month low, and reported a wider-than-expected quarterly loss despite exceeding revenue forecasts.
At $26.33 a share, Jonathan Allan sells 627 shares of Stoke Therapeutics (STOK).
Jonathan Allan, General Counsel & Corp Sec of Stoke Therapeutics (STOK), sold 627 shares of common stock at $26.33 per share on October 2, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2025. Following the sale, Allan's direct holdings in the company are 20,598 shares.
Officer Jonathan D. Allan proposes selling 627 shares of Stoke Therapeutics (STOK).
Jonathan D. Allan, an officer at Stoke Therapeutics (STOK), has proposed selling 627 common shares, valued at approximately $16,308.27, with an approximate sale date of October 2, 2026. These shares were acquired through restricted stock units on September 30, 2026. The notice also indicates that Allan sold 2,861 shares on August 18, 2026, totaling $91,639.43, within the preceding three months.
Stoke Therapeutics stock sits 35.28 percent below its high as Bo Cumbo joins board
Stoke Therapeutics' stock is trading 35.28% below its 52-week high after the company appointed Bo Cumbo to its board of directors. Cumbo brings over 30 years of biopharmaceutical experience and will help advance Stoke's investigational drug, zorevunersen, for Dravet syndrome. The company reported a significant increase in Q2 2026 revenue but also a deeper net loss, with stock facts and upcoming earnings outlined.
A passive stake at Stoke Therapeutics (STOK) includes 76,938 shares in a managed account.
BVF Partners L.P. and affiliated entities have filed a Schedule 13G for Stoke Therapeutics (STOK), indicating a passive beneficial ownership of approximately 5.6% of the company's common stock as of September 30, 2026. This ownership, totaling 3,608,968 shares, includes 76,938 shares held in a Partners Managed Account. The reported percentages are based on 64,526,242 shares outstanding as of July 30, 2026.
BVF Partners Reveals 5.6% Ownership Stake in Stoke Therapeutics Inc. (NASDAQ:STOK)
BVF Partners L.P. and associated entities have disclosed a 5.6% beneficial ownership stake in Stoke Therapeutics, Inc. (NASDAQ:STOK), totaling 3,608,968 shares. The filing, dated September 30, 2026, details shared voting and dispositive powers among the BVF group, with Mark N. Lampert also identified with shared beneficial ownership of the same amount of shares. This coordinated holding was triggered on September 23, 2026, and involves several BVF-affiliated funds.
Stoke Therapeutics stock reports USD 9.33 million Q2 revenue
Stoke Therapeutics reported Q2 2026 revenue of $9.33 million, significantly exceeding the consensus forecast of $4.89 million. Despite this revenue beat, the company posted an EPS loss of $0.93, which was deeper than the anticipated loss of $0.80 per share. Analysts maintain a "Moderate Buy" consensus with an average 12-month target of $44.25, indicating that the company's development pipeline is a key valuation driver, even as it continues to operate at a loss.
Bank of America Corp DE Makes New Investment in Stoke Therapeutics, Inc. $STOK
Bank of America Corp DE has made a new investment in Stoke Therapeutics (NASDAQ:STOK), purchasing over 259,000 shares valued at approximately $8.5 million during the second quarter. Other institutional investors like BlackRock and Redmile Group also increased their stakes in the biotechnology company. Despite missing quarterly EPS expectations and reporting significant losses, analysts maintain a "Moderate Buy" rating with an average price target of $44.25 for STOK.
Form 4 Stoke Therapeutics Inc For: 26 September By Investing.com
This article announces the filing of Form 4 for Stoke Therapeutics Inc. on September 26, 2026. Form 4 is a document filed with the SEC to report changes in beneficial ownership of a company's securities by insiders. The article provides financial market data and related news but no specific details from the Form 4 itself.
Form 4 Stoke Therapeutics Inc For: 26 September By Investing.com
This article reports on the filing of a Form 4 for Stoke Therapeutics Inc. on September 26. The brief announcement provides the company name and filing date, indicating a regulatory disclosure of insider transactions. The rest of the content is standard Investing.com interface elements, popular searches, news, and market data.
Stoke Therapeutics (STOK) grants director Alexander Cumbo options priced at $26.11 per share.
Stoke Therapeutics director Alexander Cumbo was granted 39,674 stock options at an exercise price of $26.11 per share, expiring on September 22, 2036. The options will vest in quarterly installments over three years, with the first vesting on December 23, 2026, contingent on Cumbo's continued service. This transaction was reported in a Form 4 SEC filing.
[Form 3] Stoke Therapeutics, Inc. Initial Statement of Beneficial Ownership
This SEC Form 3 filing reports the initial statement of beneficial ownership for Alexander Cumbo, a new Director at Stoke Therapeutics, Inc. (STOK). The filing indicates that Mr. Cumbo beneficially owns no securities as of September 23, 2026, the date of the event requiring the statement. The document provides standard information required for initial insider filings, including company and individual details.
Stoke Therapeutics (STOK) Board Change Puts Valuation Back In Focus
Stoke Therapeutics (STOK) recently announced a board change, with Edward Kaye stepping down and Bo Cumbo joining, bringing commercial experience in rare disease therapies. Despite a sharp share price retreat (24% down last month, 18% YTD), the company is seen by some investors as 44% undervalued with an implied fair value of $45.10. However, risks remain regarding Phase 3 data and pricing pressures, and its P/B ratio of 4.7x is above the US Biotech average of 2.1x, suggesting differing valuation perspectives.
Stoke Therapeutics appoints Bo Cumbo to board of directors
Stoke Therapeutics (NASDAQ:STOK) has appointed Bo Cumbo to its Board of Directors, bringing over 30 years of biopharmaceutical industry experience. Edward Kaye, M.D., has retired from the board but will continue to advise during the transition. The company is developing zorevunersen for Dravet syndrome, with potential FDA approval in early 2028, and has a strategic collaboration with Biogen (NASDAQ:BIIB) for its commercialization.
ETFs Investing in Stoke Therapeutics, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Stoke Therapeutics, Inc. It provides details for each ETF including market value of Stoke holdings, weight in the fund, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return. The information helps investors understand how different ETFs offer exposure to Stoke Therapeutics, Inc. with varying characteristics.
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - September 16, 2026
Stoke Therapeutics announced the grant of stock options to nine new employees as an inducement to their employment, in accordance with Nasdaq Listing Rule 5635(c)(4). These options cover an aggregate of 53,175 shares of common stock, with an exercise price of $28.15 per share, matching the closing price on September 15, 2026. The options will vest over a four-year period, subject to continued employment.
Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK
Legal & General Group Plc has acquired 35,705 shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) valued at $1.17 million, becoming a new institutional investor in the company. Other major institutions like BlackRock, RTW Investments, and State Street also increased their stakes. Despite a recent earnings miss on EPS, the company's revenue exceeded expectations, and analysts maintain a "Moderate Buy" rating with an average price target significantly above its current trading price.
Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK
Bank of New York Mellon Corp has made a new investment in Stoke Therapeutics, acquiring 164,273 shares valued at approximately $5.4 million, representing 0.26% of the company. Despite missing earnings expectations, Stoke Therapeutics has a "Moderate Buy" consensus rating from analysts with an average price target of $44.25, significantly above its current trading price. Insider selling has also occurred, with approximately $1.07 million in stock sold over the past 90 days, some of which was for tax obligations or under pre-arranged trading plans.
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics and Biogen presented long-term clinical data on zorevunersen, an investigational medicine for Dravet syndrome, at the 16th European Epilepsy Congress. Data from Phase 1/2a and open-label extension studies demonstrated substantial and durable reductions in seizures, including severe types, and continuous improvements in cognition and behavior over four years. Zorevunersen was generally well-tolerated, and Phase 3 EMPEROR study results are expected in Q3 2027 to support regulatory submissions.
Stoke Therapeutics CMO Barry Ticho Executes 5,545 Share Sales Under 10b5-1 Plan
Barry Ticho, Chief Medical Officer of Stoke Therapeutics (NASDAQ:STOK), sold a total of 5,545 common stock shares on September 1, 2026, under a pre-established Rule 10b5-1 trading plan. The sales were executed in two transactions at weighted average prices of $30.512 and $31.0569 per share, respectively. Following these transactions, Ticho retained direct beneficial ownership of 20,110 shares.
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock
Stoke Therapeutics (NASDAQ:STOK) insider Barry Ticho sold 5,545 shares of the company's stock for $170,065.15 on September 1st, reducing his ownership by over 21%. This sale was part of a pre-arranged trading plan, and he had made earlier sales in August. Despite a recent quarterly loss, analysts maintain a "Moderate Buy" rating with a consensus price target significantly above the current trading price.
Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome By Investing.com
Stoke Therapeutics Inc. and Biogen Inc. presented 4-year data from open-label extension studies of zorevunersen for Dravet syndrome, showing sustained improvements in cognition, behavior, and seizure reduction with a generally well-tolerated safety profile. The global Phase 3 EMPEROR study is currently underway, with results expected in the third quarter of 2027. Zorevunersen, an investigational antisense oligonucleotide, aims to increase functional NaV1.1 protein production and has received various orphan drug and breakthrough therapy designations.
Stoke Therapeutics, Inc. $STOK Shares Acquired by Wellington Management Group LLP
Wellington Management Group LLP increased its stake in Stoke Therapeutics (NASDAQ:STOK) by 13.7% in the second quarter, acquiring over 423,000 additional shares. Several other institutional investors also raised their holdings, though company insiders sold nearly $900,000 worth of shares in the past three months. Despite missing earnings expectations, analysts generally maintain a "Moderate Buy" rating with a $44.25 average price target for the stock.
Stoke Therapeutics to Present at the Cantor Global Healthcare Conference
Stoke Therapeutics announced that its CEO and Chief Patient Officer will present at the Cantor Global Healthcare Conference on September 9, 2026. The presentation will focus on the company's RNA medicine approach and its lead investigational drug, zorevunersen, for Dravet syndrome. A live webcast will be available on the company's investor relations website.
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Stoke Therapeutics and Biogen announced presentations of 4-year clinical data from open-label extension studies of zorevunersen for Dravet syndrome at the 16th European Epilepsy Congress. The data highlight sustained improvements in cognition, behavior, and durable seizure reductions, along with a well-tolerated safety profile. These findings support zorevunersen's potential as a first-in-class disease-modifying treatment for Dravet syndrome, targeting the underlying genetic cause.
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Recommendation of "Moderate Buy" from Analysts
Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $44.25, significantly above its current share price of $31.62. Despite positive analyst sentiment, the company reported a quarterly adjusted loss of $0.93 per share, missing expectations, though revenue exceeded estimates. Insider selling has occurred, but institutional investors have increased their holdings, indicating mixed signals for the stock.
57,784 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Deutsche Bank AG
Deutsche Bank AG recently acquired 57,784 shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) valued at approximately $1.89 million, representing a 0.09% stake. Despite missing analyst EPS expectations, Stoke Therapeutics' revenue exceeded estimates, and Wall Street analysts generally maintain a "Moderate Buy" rating with a consensus price target of $44.25. Insider selling also occurred, with 30,623 shares sold for about $953,765.
Palo Alto Investors LP Invests $2.77 Million in Stoke Therapeutics, Inc. $STOK
Palo Alto Investors LP has invested $2.77 million in Stoke Therapeutics (NASDAQ:STOK) by acquiring 84,631 shares. This move comes as other institutional investors have also adjusted their positions, despite the company missing its recent quarterly EPS expectations while exceeding revenue estimates. Analysts largely maintain a "Moderate Buy" rating with a consensus price target of $44.25, even though insiders have sold a significant number of shares recently.
Jupiter Topco LLC Takes $59.36 Million Position in Stoke Therapeutics, Inc. $STOK
Jupiter Topco LLC recently acquired a significant position in Stoke Therapeutics, Inc. (NASDAQ:STOK), purchasing 1.81 million shares valued at approximately $59.36 million. This makes Jupiter Topco LLC a 2.81% stakeholder in the company. Despite missing earnings per share estimates, Stoke Therapeutics' revenue exceeded expectations, and analysts generally maintain a "Moderate Buy" rating with a consensus target price of $44.25.
Parkman Healthcare Partners LLC Takes Position in Stoke Therapeutics, Inc. $STOK
Parkman Healthcare Partners LLC has acquired a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK) with 355,443 shares valued at approximately $11.6 million. Other institutional investors like BlackRock and Janus Henderson also increased their holdings, while company insiders sold shares to cover tax obligations. Despite missing EPS estimates, analysts maintain a "Moderate Buy" rating with an average price target of $44.25 for Stoke Therapeutics.
J.P. Morgan Upgrades Stoke Therapeutics(STOK.US) to Buy Rating, Raises Target Price to $40
J.P. Morgan has upgraded Stoke Therapeutics (STOK.US) from a Neutral to a Buy rating, while also increasing its target price from $25 to $40. This upgrade suggests a significant positive outlook for the company's stock from the investment bank.
STOK Reinstated by JP Morgan -- Price Target Set at $40
JP Morgan has reinstated coverage on Stoke Therapeutics (STOK) with an Overweight rating and a price target of $40.00, signaling renewed confidence in the biotechnology company's potential. Despite this optimistic analyst view, GuruFocus indicates that STOK is significantly overvalued at its current price of $32.18, with a GF Value™ of $9.65 and a mixed GF Score™ of 44/100, reflecting concerns about its profitability and valuation. Insider selling activity also suggests caution for investors.
Stoke Therapeutics (NASDAQ:STOK) Earns Overweight Rating from Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. initiated coverage on Stoke Therapeutics (NASDAQ:STOK) with an "overweight" rating and a $40 price target, suggesting a potential upside of over 25%. This positive outlook aligns with a broader analyst consensus of "Moderate Buy" and an average price target of $44.25 for the company. Despite missing earnings expectations with a loss of $0.93 per share, Stoke Therapeutics exceeded revenue forecasts, driven by its development of genetic medicines like STK-001 for Dravet syndrome.
STOK Looks 225.6% Overvalued on GF Value™
JPMorgan analyst Jessica Fye reinitiated coverage on Stoke Therapeutics Inc (NASDAQ: STOK) with an Overweight rating and a $40 price target, driven by confidence in its Phase III EMPEROR trial. Despite this, GuruFocus assesses STOK as 225.6% overvalued based on its GF Value™ of $9.65, with a high Price-to-Sales ratio of 70.77, weak profitability, and significant insider selling, signaling caution for investors.
Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating
Stoke Therapeutics (NASDAQ:STOK) shares rose in pre-market trading after JPMorgan initiated coverage with an Overweight rating and a $40 price target, reinforcing an already bullish analyst consensus. The company recently completed enrollment for its Phase 3 EMPEROR study for zorevunersen, a treatment for Dravet syndrome, and has financial resources projected through early 2028. This positive analyst support and clinical progress are contributing to investor interest despite the stock trading below its 52-week high.
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 7.9% - What's Next?
Stoke Therapeutics (NASDAQ:STOK) saw its stock price drop by 7.9% to $30.42 after reporting an EPS loss of $0.93, missing consensus estimates despite exceeding revenue expectations. Despite the recent dip and insider sales, analysts maintain a "Moderate Buy" rating with an average target price of $43.00, suggesting significant upside. The company is developing STK-001 for Dravet syndrome using its TANGO platform, and institutional investors have been adjusting their positions.
Bank of America Corp DE Buys 336,931 Shares of Stoke Therapeutics, Inc. $STOK
Bank of America Corp DE significantly increased its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 163.4% in the first quarter, now owning 543,095 shares valued at $17.68 million. Other institutional investors like RTW Investments LP and Redmile Group LLC also boosted their holdings. Despite recent insider selling, the stock currently holds a "Moderate Buy" consensus rating from analysts with a target price of $43.00.
Is Strong EMPEROR Trial Enrollment and Retention Altering The Investment Case For Stoke Therapeutics (STOK)?
Stoke Therapeutics' Phase III EMPEROR trial for zorevunersen in Dravet syndrome has exceeded its 150-patient enrollment goal, reaching 162 patients with no discontinuations, which is expected to strengthen confidence as the company approaches regulatory milestones. This positive development could influence the investment narrative, with plans to begin a rolling FDA New Drug Application in Q1 2027 and complete it by Q3 2027. Despite ongoing losses, the strong trial execution is a key near-term catalyst, though the biggest risk remains whether full Phase III data will confirm earlier positive results.
Stoke Therapeutics’ director Kaye sells $402,528 in shares
Stoke Therapeutics' director, Edward M. Kaye MD, recently sold shares totaling $402,528 to cover tax withholding liabilities related to restricted stock units. This transaction involved the disposal of 11,930 shares at prices between $31.40 and $32.36, and another 637 shares between $32.44 and $32.54. Dr. Kaye still directly holds 124,557 shares, following an acquisition of 26,250 shares through performance stock units just prior to these sales.
Stoke therapeutics CMO Barry Ticho sells $152k in stock
Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold shares worth $152,689 on August 18, 2026, to cover tax liabilities from restricted stock unit vesting, following his acquisition of 10,000 shares from performance stock units. This transaction occurred amidst recent financial disclosures by Stoke Therapeutics, including a wider-than-expected Q2 2026 loss but significant revenue beat, and progress in its Dravet syndrome program, zorevunersen.
Stoke Therapeutics (NASDAQ: STOK) CMO gets 10,000 shares, sells some for taxes
Stoke Therapeutics' Chief Medical Officer, Barry Ticho, exercised 10,000 performance stock units on August 14, 2026, converting them into common stock. Subsequently, on August 18, 2026, he sold 4,767 shares (4,525 and 242) in issuer-mandated transactions to cover tax withholding liabilities associated with the vesting of restricted stock units. These shares were sold at weighted average prices around $32 per share, resulting in approximately $153,000 in gross sale proceeds.
Stoke therapeutics CMO Barry Ticho sells $152k in stock
Barry Ticho, Chief Medical Officer at Stoke Therapeutics (NASDAQ:STOK), sold shares worth $152,689 on August 18, 2026, to cover tax liabilities from restricted stock unit vesting. These sales followed his acquisition of 10,000 shares through vested performance stock units on August 14, 2026. Despite the stock being potentially overvalued by some metrics, it has shown a 74% return over the past year.
Stoke Therapeutics general counsel Allan sells $91,639 in stock
Jonathan Allan, General Counsel at Stoke Therapeutics, sold 2,861 shares of company stock worth $91,639 to cover tax liabilities related to restricted stock unit vesting. This sale occurred on August 18, 2026, after he acquired 6,000 shares from vested performance stock units on August 14, 2026. The stock is performing well, and the company recently reported strong revenue growth, attributed to its lead Dravet syndrome program, zorevunersen, despite a wider-than-expected loss.
Stoke Therapeutics’ director Kaye sells $402,528 in shares
Edward M. Kaye MD, a director at Stoke Therapeutics, Inc. (NASDAQ:STOK), recently sold shares worth $402,528 to cover tax liabilities related to restricted stock unit vesting. These transactions occurred on August 18, 2026, following his acquisition of 26,250 shares through performance stock units on August 14, 2026. Despite the stock's 74% return over the past year, InvestingPro analysis suggests it is slightly overvalued as the company is not yet profitable.
Stoke therapeutics CMO Barry Ticho sells $152k in stock By Investing.com
Barry Ticho, Chief Medical Officer at Stoke Therapeutics (NASDAQ:STOK), sold $152,689 worth of company stock on August 18, 2026, to cover tax withholding liabilities from vested restricted stock units. This sale occurred after he acquired 10,000 shares through vested performance stock units on August 14, 2026. Despite the stock potentially being overvalued according to InvestingPro analysis, it has seen a 74% return over the past year.
Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 2,861 Shares
Stoke Therapeutics' General Counsel, Jonathan Allan, sold 2,861 shares of the company's stock for approximately $91,638 to cover tax withholdings from vested equity awards, reducing his holdings by 11.88%. Despite missing earnings per share estimates, the company's revenue exceeded expectations. Analysts maintain a "Moderate Buy" rating with an average price target of $43, significantly higher than the current stock price.
Is Stoke Therapeutics (STOK) A Bargain On Its EMPEROR Trial Enrollment Milestone?
Stoke Therapeutics (STOK) is gaining attention after its Phase III EMPEROR trial for Dravet syndrome enrolled 162 patients, exceeding its 150-patient target without discontinuations. The stock has seen significant returns over the past year, and analysts currently peg its fair value at $45.10, suggesting it is 28.7% undervalued compared to its current share price of $32.14. However, potential trial underperformance and future pricing decisions for zorevunersen remain key risks.
Edward Md Kaye Sells 12,567 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock
Director Edward Md Kaye sold 12,567 shares of Stoke Therapeutics (NASDAQ:STOK) stock for approximately $402,521 to cover tax withholding obligations from vested equity awards, reducing his direct ownership by 9.16%. The company reported a quarterly loss of $0.93 per share, missing consensus estimates, but revenue of $9.32 million exceeded expectations. Despite unprofitability, analysts maintain a "Moderate Buy" rating with an average price target of $43.00.
